Abstract. Osteosarcoma (OS) is an aggressive malignant neoplasm that arises from primitively transformed cells of mesenchymal origin, and that exhibits osteoblastic differentiation and produces malignant osteoid. MicroRNAs (miRNAs) have been widely reported to have important regulatory roles in various human tumors, including OS. However, the potential mechanism of miR-29 in OS remains largely unknown. miR-29 was highly expressed in OS and overexpression of miR-29 promoted OS cell proliferation, as well as proliferating cell nuclear antigen (PCNA) expression and migration, whereas lower expression of miR-29 inhibited OS cell proliferation, PCNA expression and migration. In the present study, a dual-luciferase reporter system supporting phosphatase and tensin homolog (PTEN) was a target of miR-29 and its expression was inhibited by miR-29 mimic, but increased by miR-29 inhibitor. Overexpression of PTEN inhibited OS cell proliferation and migration and it could attenuate miR-29 promotion effect on OS progression. Overall, the results revealed that miR-29, as a tumor promoter, is involved in OS progression and metastasis by targeting PTEN, indicating that the miR-29/PTEN pathway is a potential therapeutic target for the treatment of OS.
Introduction
Osteosarcoma (OS) is a malignant bone tumor characterized by tumor cells directly forming bone or bone tissues. It often occurs in adolescents or children under the age of 20 and the prognosis is poor (1-3). The current treatment strategy focuses on primary tumors, but it is limited in the treatment of metastatic OS (4) . Thus, treating metastatic OS is now a great challenge for oncologists. It is necessary for us to understand the pathogenesis and biological characteristics of metastatic OS and to find new targets and biomarkers for the treatment of OS patients is urgent (5, 6) .
It is known that, miRNAs can extensively disrupt various functions of different cancers by targeting mRNA (7) , and the target mRNA is also proven to regulate cell proliferation, invasion and apoptosis (8) . New evidence suggests that miRNAs are involved in human carcinogenesis, including promoting or inhibiting tumor development (9, 10) . For example, miR-365, miR-124a, miR-625 and miR-141 acted as tumor suppressors in OS (11) (12) (13) (14) , while miR-504, miR-19 and miR-93 promoted OS cell progression (15) (16) (17) .
The miR-29 family contains three mature members (miR-29a, miR-29b and miR-29c). An increasing number of studies have shown the decreased expression of miR-29 family in various types of cancer and that it has the ability to suppress tumors, including breast, bladder and pancreatic cancer (18) (19) (20) . Shin et al found that miR-29b effect on glioblastoma was suppressive (21) . Ma et al stated that, miR-29 suppressed schwannoma cell proliferation and motility by regulating CDK6 (22) . In colon cancer, miR-29 showed inhibitory effect on cell invasion and migration by regulating MMP2 (23) . Additionally, miR-29 suppressed lung cancer development by targeting DNMT3A and DNMT3B (24) . However, role of miR-29 in OS and its mechanism have rarely been reported.
It is well known that phosphatase and tensin homolog (PTEN) acts as a tumor suppressor and PTEN expression was proved abnormal in many cancers (25) . For instance, PTEN functioned as a tumor inhibitor in regulating pancreatic cancer progression regulated by miR-32 (26) . miR-21 modulated gastric cancer development via targeting PTEN (27) and PTEN was also a target of miR-20b in modulating prostate cancer cell viability and migratory ability (28) . However, the effect of PTEN on OS cell migration and proliferation and whether PTEN is regulated by miR-29 in OS have yet to be reported.
In our study, miR-29 and PTEN in OS and its potential mechanism in modulating OS cell migration and proliferation was investigated. Our results may provide important insight into the prognosis and treatment of OS.
Materials and methods

OS specimens.
We collected conventional OS and adjacent non-cancerous tissues from 60 patients who underwent resection surgery in the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) between February 2010 and August 2016. None of OS patients had received radiotherapy or chemotherapy before surgery and the tissues were diagnosed as OS by pathologists. All tissue specimens were placed into liquid nitrogen immediately and stored at -80˚C in a refrigerator for use in subsequent experiments. The Ethics Committee of Zhengzhou University approved this study and the patients signed informed consent prior to surgery.
Cell lines and cell culture. The purchased OS cell lines (MG-63, U2OS, 143B, Saos-2) were cultured in RPMI-1640 medium at 37˚C and the medium contained 20% FBS and penicillin (100 U/ml) and streptomycin (100 µg/ml). hFOB1.19 (normal human osteoblast) cells were cultured in DMEM supplemented with 10% FBS and G418 (0.03 mg/ml) at 34˚C with 5% CO 2 . OS cell lines (MG-63, U2OS, 143B, Saos-2) and hFOB1.19 (normal human osteoblast) cells were obtained from ATCC (Manassas, VA, USA).
Cell transfection. miR-29 mimic or inhibitor provided by Suzhou GenePharma Co., Ltd. (Suzhou, China) was transfected into MG-63 cells to facilitate or inhibit miR-29 expression and control mimic were used as control (con). We added MG-63 cells into 24-well plates containing medium and we performed transfection using Lipofectamine 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 48 h. PTEN vector and con vector were synthesized by GenePharma Co., Ltd. and they were used to enforce PTEN expression and acted as a control separately.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA and microRNA were extracted from OS tissues and cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Complementary DNA was synthesized using PrimeScript RT reagent kit and RT-qPCR was performed using SYBR Premix Ex Taq (both from Takara Biotechnology Co., Ltd., Dalian, China) with the Stratagene Mx3000P real-time PCR system (Agilent Technologies, Inc., Santa Clara, CA, USA). The primer sequences used were: miR-29-F: TGCCAGGAGCTGGTGATTTCCT, miR-29-R: ACGGGCGTACAGAGGATCCCC. PTEN-F: GTGCAG ATAATGACAAG, PTEN-R: GATTTGACGGCTCCTCT. proliferating cell nuclear antigen (PCNA)-F: GGTGTTG GAGGCACTCAAGG, PCNA-R: CAGGGTGAGCTGCACC AAAG. U6-F: CTCGCTTCGGCAGCAC, U6-R: ACGCTTC ACGAATTTGC. β-actin-F: GA TCATTGCTCCTCCTGAGC; β-actin-R: ACTCCTGCTTGCTGATCCAC. U6 and β-actin were used as internal controls. Relative expression of miR-29, PTEN and PCNA was calculated by the 2 -ΔΔCq method (29) .
Western blot analysis. Lysis buffer containing protease inhibitor and phenylmethanesulfonyl fluoride (PMSF) was added into OS tissues or cells and then homogenized on ice (the written informed consent from patients were obtained). After centrifugation at 12,000 x g, at 4˚C for 30 min, the supernatant was measured by BCA kit. Then, 50 µg protein specimens at the same concentration were added onto sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Proteins were then transferred to polyvinylidene fluoride 5 /well) with different transfection were placed into the top chambers and DMEM containing 10% FBS into lower chambers and then cultured for 48 h at 37˚C under CO 2 atmosphere. The cells from the top chambers migrated into the lower chambers, and the cells on the top chambers were removed with cotton. The cells were fixed on lower chambers using 4% formaldehyde for 30 min at room temperature (25˚C), cells were stained with 0.1% crystal violet for 15 min, and images of the cells were captured using an inverted microscope (Nikon 80i, Feasterville, PA, USA). Cells were then counted using Living Image Version 4.5 Software (PerkinElmer, Inc., Waltham, MA, USA) image software.
MTT assay. Fresh culture (100 µl) medium was added into 96-well plates to replace the culture medium when the MG-63 cell population reached optimal densities. Then, MTT reagent (20 µl) was added and cultured at 37˚C for 4 h. Subsequently, the MTT medium was sucked out and 100 µl of DMSO was added for additional 10 min, the plates were read at a wavelength of 570 nm using the multilabel plate reader (PerkinElmer, Inc.) at 1, 2, 3, 4 days to measure the absorbance of each well.
Luciferase reporter assay. TargetScan Human 7.1 was firstly carried out to identify the possible targets of miR-29. We used Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) to co-transfect miR-29 mimic or control mimic with 3'-UTR of wild or mutated PTEN in MG-63 cells. The dual luciferase reporter system (GeneCopoeia, Inc., Rockville, MD, USA) was then used to measure the luciferase activity of MG-63 cells treated with different transfection.
Statistical analysis. All experiments were repeated three times independently. SPSS v.19.0 software (IBM Corp., Armonk, NY, USA) was used to perform statistical analyses and GraphPad Prism 5.02 software (GraphPad Software, Inc., La Jolla, CA, USA) to complete graph presentations. Results are presented as the mean ± standard deviation, and the data were evaluated using Student's t-test or Tukey's post hoc test after ANOVA in SPSS. P<0.05 was considered to indicate a statistically significant difference. 
Results
miR-29 is overexpressed in OS.
Our primary aim was to explore miR-29 role in OS. First, we detected miR-29 level in OS tissues and cells using RT-qPCR. As shown in Fig. 1A , miR-29 average level in OS tissues was significantly increased compared with normal tissues. miR-29 expression in OS cells (MG-63, U2OS, 143B, Saos-2) was also elevated compared to normal cells (hFOB1.19), as expected (Fig. 1B) . miR-29 expression was also detected in various stages of OS tumors and the results showed that the more advanced the tumor stage, the higher the expression of miR-29 (Fig. 1C) , indicating that miR-29 may participate in OS malignant progression.
miR-29 mimic promotes OS cell proliferation and migration.
Secondly, we measured miR-29 effect on OS progression. We overexpressed miR-29 in MG-63 cells using miR-29 mimic, and mRNA expression was increased significantly (Fig. 2A) . Cell proliferation was measured by MTT assay and RT-qPCR.
MTT results showed that cell viability in miR-29 mimic group was enhanced in comparison with control mimic group (Fig. 2B ). PCNA is a marker for cell proliferation (30, 31) . RT-qPCR analysis found that PCNA expression was increased in miR-29 mimic group (Fig. 2C ). Cell migration measured by Transwell demonstrated that miR-29 mimic promoted OS cell migratory ability (Fig. 2D) . The results above demonstrated a promotion effect of miR-29 on OS progression. 
Silencing miR-29 curbed OS cell proliferation and migration.
We then silenced miR-29 using miR-29 inhibitor to further confirm its effect on OS. The transfection efficiency is shown in Fig. 3A , miR-29 inhibitor group decreased miR-29 expression. As we expected, MTT results showed the decreased cell viability in miR-29 inhibitor group in comparison with the con-inhibitor group (Fig. 3B) . RT-qPCR analysis revealed the increased PCNA expression in MG-63 cells after silencing miR-29 (Fig. 3C ). Cell migration measured by Transwell showed enhanced cell migratory ability in miR-29 inhibitor group than the con-inhibitor group (Fig. 3D) . The results above indicated that silencing miR-29 inhibited the development of OS.
miR-29 targets PTEN in OS.
The next step was to investigate miR-29 molecular mechanism in OS. TargetScan Human 7.1 was carried out to identify the possible targets of miR-29 and results are shown in Fig. 4A . As further confirmation, we assessed PTEN protein and mRNA level after MG-63 cell restoration or inhibiting miR-29 via western blot analysis and RT-qPCR. PTEN expression was reduced when miR-29 was restored while increased when inhibiting miR-29 (Fig. 4B) . Then, luciferase reporter assay was carried out to determine whether PTEN was a direct target of miR-29 in OS. The luciferase activity of miR-29 mimic group was decreased but increased in miR-29 inhibitor group in wild-type. However, there was no significant effect in mut type (Fig. 4C) . The results verified PTEN as a direct target of miR-29. In addition, miR-29 and PTEN expression were negatively correlated (Fig. 4D) .
PTEN attenuates miR-29 promotion effect on OS progression.
Then, we investigated the role of PTEN in OS and whether PTEN affected the miR-29 role in regulating OS progression. PTEN was overexpressed by PTEN vector due to its lower expression in OS. The results showed that PTEN expression was higher after cells were transfected with PTEN vector (Fig. 5A) . PTEN overexpressed could inhibit OS cell migration and proliferation ( Fig. 5B and C) . Subsequently, miR-29 mimic and PTEN vector were co-transfected into MG-63 cells to test the role of PTEN in OS regulated by miR-29. The cell viability and PCNA expression were both increased obviously by miR-29 mimic in comparison with control (Fig. 5D) . By contrast, overexpression of both miR-29 and PTEN, cell proliferation was reduced compared with overexpression of miR-29 alone, indicating that PTEN could attenuate miR-29 promotion effect on cell proliferation. Additionally, the migration results suggested that miR-29 promotion increased migration in OS cells compared with control, whereas promoting both 
Discussion
An increasing number of studies have reported the important roles of miRNAs in tumorigenesis and tumor development (32) . Furthermore, the ability to control cell growth, metastasis and survival may serve essential roles in preventing and treating various human malignancies, including OS (33) . miR-29 was reported to have significant inhibitory effect on various cancers. For example, it inhibited hepatocellular carcinoma cell migration and proliferation by regulating IGF1R (34) . miR-29 played a tumor suppressive role in modulating gliomas through targeting CDC42 (35) . However, Gao et al reported that miR-29 played a promoting role in OS (36) and Hong et al showed the same discovery that miR-29 expression was higher in OS patients (37) . Those results were in line with our findings that miR-29 expression was upregulated in OS tissues and cells, but these studies did not show the function of miR-29 in OS tumorigenesis and development. In the present study, we first demonstrated that restoration of miR-29 facilitated cell migration and proliferation, while inhibiting miR-29 showed inhibitory effect. PTEN was the first tumor suppressor gene found with a bispecific phosphatase activity and closely associated with carcinoma (38) . PTEN suppressed the migration and genetic deletion of the PTEN tumor suppressor gene, promoting cell motility and overexpression or reconstitution of PTEN and inhibiting cell motility in a variety of cell types (39, 40) . Hundreds of genes were found to be the target of miRNA, which harbors the target sequence in their 3'-UTR complementary to the seed region of the miRNA. PTEN was also proven to be a target of miRNAs in modulating cancer progression. PTEN was the target of miR-28 and suppressed gastric cancer cell proliferation and invasion (41) . Additionally, it suppressed renal cancer cell proliferation as a target of miR-30a (42). Zhao et al reported that PTEN regulated OS cell growth and apoptosis and acted as a target of miR-19 (43) . We also found that the PTEN mRNA expression was downregulated in MG63 cells compared with the hFOB1.19 cells (data not shown). However, the underlying mechanism between miR-29 and PTEN was still unclear in OS. In our study, we found that miR-29 could negatively regulate the expression of PTEN in MG63 cells. Further investigation was conducted to explore the molecular mechanism how PTEN promoted OS cell proliferation and migration. In addition, PTEN overexpressed was proved to inhibit OS cell proliferation and migration, PTEN could reverse miR-29 promotion effect on OS progression as well. Therefore, to the best of our knowledge, the present study provided an effective treatment target in OS.
In conclusion, miR-29 facilitated OS migration and proliferation and this is the first report that miR-29 targeted PTEN and regulated OS development. Furthermore, PTEN could reverse miR-29 promotion effect on OS providing a new idea for OS therapy.
